Monogenic causes account for up to 20% of nephrolithiasis instances and are crucial for developing targeted treatments. Whole-exome sequencing, genome-wide association, candidate gene, and in vitro and animal functional studies are crucial to identify these mutations. Therapies targeting monogenic variants, such as RNA-interference-based treatments, have been successfully used to treat monogenic disorders.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Howles, S. A. & Thakker, R. V. Genetics of kidney stone disease. Nat. Rev. Urol. 17, 407–421 (2020).
Majmundar, A. J. et al. OXGR1 is a candidate disease gene for human calcium oxalate nephrolithiasis. Genet. Med. 25, 100351 (2022).
Khaleel, A. et al. A single nucleotide polymorphism (rs4236480) in TRPV5 calcium channel gene is associated with stone multiplicity in calcium nephrolithiasis patients. Mediators Inflamm. 2015, 375427 (2015).
Howles, S. A. et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat. Commun. 10, 5175 (2019).
Enerbäck, S. et al. Acidosis and deafness in patients with recessive mutations in FOXI1. J. Am. Soc. Nephrol. 29, 1041–1048 (2018).
Tsai, F.-J., Lin, C.-C., Lu, H.-F., Chen, H.-Y. & Chen, W.-C. Urokinase gene 3’-UTR T/C polymorphism is associated with urolithiasis. Urology 59, 458–461 (2002).
Chou, Y.-H. et al. A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. J. Urol. 185, 1742–1746 (2011).
Lu, X. et al. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511, 127–130 (2012).
Garrelfs, S. F. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216–1226 (2021).
Baum, M. A. et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 103, 207–217 (2023).
Acknowledgements
The authors acknowledge J. Badreddine for their assistance in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.-H.W.W. has clinical trials with Moderna Tx and is in the executive committee of the Harrington Scholar-Innovator award programme. D.B. has Fortec litho stock. M.B. has clinical trials with NovoNordisk, is a scientific advisor with NovoNordisk, has an ongoing post-marketing study with Alynylam, is a scientific advisor with Alnylam and is a medical advisor with Cantero (previously Orfan) and Chinook. F.H. has a University of Michigan patent, a patent of NPHP4 planned and is part of the Brigham & Women’s Hospital Boards course. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Wu, CH.W., Huang, YR., Bodner, D. et al. The evolving landscape of monogenic nephrolithiasis and therapeutic innovations. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00880-0
Published:
DOI: https://doi.org/10.1038/s41585-024-00880-0
